Carcinoma of the breast and hormone replacement therapy for osteoporosis

International Journal of Clinical Practice

Volumn 54, Issue 2, 2000, Pages 99-103

  Crawshaw, A ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; ESTROGEN RECEPTOR; ETIDRONIC ACID; PHYTOESTROGEN; RALOXIFENE; TAMOXIFEN; TIBOLONE;

BONE DENSITY; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; ESTROGEN THERAPY; FEMALE; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

ADULT; AGED; ALGORITHMS; BREAST NEOPLASMS; CARCINOMA; ESTROGEN REPLACEMENT THERAPY; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; OSTEOPOROSIS; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL RATE;

EID: 0034116246     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Davidson NE. Hormone replacement therapy: breast versus heart versus bone. New Engl J Med 1995; 332: 1638-1639 (editorial).
2. Rodstrom K, Bengtsson C, Lissner L et al. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort in Gothenburg, Sweden. BMJ 1999; 319: 890-893.
3. Troisi R, Shairer C, Chow WH et al. A prospective study of menopausal hormones and the risk of colorectal cancer. Cancer Cause Control 1997; 8(2): 130-138.
4. Perrson I, Yuen J, Bergkvist L et al. Cancer incidence and mortality in women receiving estrogen and estrogen-protestogen replacement therapy: long term follow-up of a Swedish cohort. Int J Cancer 1996; 67(3): 327-332.
5. Sondeqvist G. Effects of sex steroids on proliferation in normal mammary tissue. Ann Med 1998; 30(6): 511-524.
6. Du Pon WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 151: 67-72.
7. Steinberg K, Thacker SB, Smith SJ et al. A meta-analysis of the effects of ERT on the risk of breast cancer. JAMA 1991; 265: 1985-1990.
8. Armstrong BK. Oestrogen therapy after the menopause: boon or bane? Med J Aust 1988; 148: 213-214.
9. Grady D, Ernster V. Does postmenopausal hormone therapy cause breast cancer? Am J Epidemiol 1991; 134: 1396-1400.
10. Sillero Arenas M, Delagado-Rodriguez M, Rodriguez-Cantera R et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynaecol 1992; 79: 286-294.
11. Colditz GA, Egan KM, Stamfer MJ. Hormone replacement therapy and the risk of breast cancer: results from epidemiological studies. Am J Obstet Gynecol 1993; 168: 1473-1480.
12. Colditz GA. Hormones and breast cancer: evidence and implications for consideration of risk and benefits of hormone replacement therapy. J Women's Health 1999; 8(3): 347-357.
13. Colditz GA, Hankinson SE, Hunter DJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 1995; 332(24): 1589-1593.
14. Wren BG. Megatrials of hormone replacement therapy. Drugs Ageing 1998; 12(5): 343-348.
15. Anon. Breast cancer and hormone replacement: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-1059.
16. Gapstur SM, Morrow M, Sellers TA et al. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of Iowa Women's Health Study. JAMA 1999; 281(22): 2091-2097.
17. O'Connor IF, Shembbekar MV, Shousha S. Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J Clin Pathol 1998; 51(12): 935-938.
18. Schairer C, Gail M, Byrne C et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 1999; 91(3): 264-270.
19. Huan Z, Hankinson SE, Colditz GA et al. Dual effect of weight and weight gain on breast cancer risk. JAMA 1997; 278(17): 407-411.
20. Cancer in south-east England 1992. Thames Cancer Registry.
21. Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 1-15, 71-85.
22. Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 929-942.
23. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 1451-1467.
24. Hortobagyi GN, Buzdae A. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin 1995; 45: 199-226.
25. Li F, Pitt PI, Sherwood R et al. Biochemical markers of bone turnover in women with surgically treated cancer of the breast. Eur J Clin Invest 1993; 23: 566-571.
26. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93-97.
27. Fogelman I. The effects of oestrogen deficiency on the skeleton and its prevention. Br J Obstet Gynaecol 1996; 103(suppl 14): 5-9.
28. Whilhite L. Osteoporosis in women: prevention and treatment. J Am Pharm Assoc 1998; 38(5): 14-22.
29. Hilliard TC, Whitecroft SJ, Marsh MS. Long term effects of transdermal and oral hormone replacement on postmenopausal bone loss. Osteopor Int 1994; 4: L341-L348.
30. Michaelsson K, Baron JA, Farahmand B et al. Swedish Hip Fracture Study Group. Hormone replacement therapy and risk of hip fracture: population based case control study. BMJ 1998; 16: 1858-1863.
31. Chang J Powles TJ, Ashley SE et al. The effect of tamoxifen and HRT on serum cholesterol, bone mineral density and coagulation factors in healthy post-menopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 1996; 7(7): 671-675.
32. Fisher B, Constanto JP. Tamoxifen for prevention of breast cancer: report of the national Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 1371-1388.
33. Clarkson TB. Cardiovascular effects of synthetic and natural estrogen receptor modulators. American Society of Clinical Oncology Educational Book. Lippincott, Williams & Wilkins 1999; 647-653.
34. Early Breast Cancer Trialists Collaborative Group. Tamoxiten for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1466.
35. Lufkin EG, Whitaker MD, Nickelsen T et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomised trial. J. Bone Min Res 1998; 13: 1747-1754.
36. Cumming SR, Norton L, Kreuger KA et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: two-year finding from the multiple outcomes of raloxifene evaluation (MORE) trial. Proc Am Soc Clin Oncol 1998; 17: A3.
37. Anon. Drug Ther Bull 1999; 37(5): 33-36.
38. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1992; 85: 1398-1406.
39. Raloxifene. Summary of product characteristics. Eli Lilly, 1998.
40. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999; 353: 571-580.
41. Rymer J, Chapman MG, Fogelman I et al. The effect of tibolone on postmenopausal bone loss. Osteopor Int 1994; 4(6): 314-319.
42. Bingham SA, Atkinson C, Liggins J et al. Phyto-oestrogens: where are we now? Br J Nutr 1998; 79(5): 393-406.
43. Sahni M, Guenther HL, Fleisch H et al. bisphosphonates act on rat bone resorption through the mediation of osteoclasts. J Clin Invest 1993; 91: 2004-2011.
44. Fogelman I, Smith L, Mazess R et al. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 1986; 24: 57-62.
45. Crawshaw A, Pitt P. Prevention of osteoporosis in premenopausal breast cancer patients. Osteopor Rev 1998; 6(1): 1-3.